Which of three structures is AZD-3199?

Abstract

AstraZeneca progressed the long acting β₂ agonist into Phase II studies for the treatment of asthma and chronic obstructive pulmonary disease in August 2008. These three applications claim specific salt forms of three different long acting β₂ agonists, all benzothiazolone derivatives. It would seem that one claims AZD-3199 whereas the other two claim backup compounds.

Keywords::

• asthma
• AZD-3199
• beta adrenoceptor
• COPD
• β₂ agonist